Zyprexa Tablets 10 mg (Olanzapine)

Adult dose

The therapeutic dose of this medicine should be adjusted according to the patient's clinical condition. Increases above the usual recommended daily dose of 10 mg are recommended only after an appropriate clinical evaluation. 1. Adults 1) Schizophrenia (1) The recommended initial dose is 5∼10 mg of olanzapine once daily. (2) Maintenance treatment: Although it is difficult to give a definitive answer regarding how long treatment with this medicine should continue, its efficacy was demonstrated in a placebo-controlled study in which patients with schizophrenia whose symptoms had stabilized after approximately 8 weeks of treatment received maintenance therapy at doses of 10∼20 mg daily for 8 months. The need for maintenance treatment at an appropriate dose should be assessed periodically. 2) Bipolar disorder (1) Treatment of manic and mixed episodes associated with bipolar I disorder The initial dose is 15 mg of this medicine once daily as monotherapy, or 10 mg once daily as adjunctive therapy with lithium or valproate. (2) Prevention of recurrence in bipolar disorder The recommended initial dose is 10 mg once daily. For patients who have been receiving this medicine to treat mania, continue the same dose to prevent recurrence. If a new manic, mixed, or depressive episode occurs, continue treatment with this medicine, together with adjunctive therapy to treat mood symptoms as clinically indicated (optimizing the required dose). 3) For schizophrenia; treatment of manic and mixed episodes associated with bipolar I disorder; and prevention of recurrence in bipolar disorder, the daily dose may be adjusted within the range of 5 mg to 20 mg based on clinical status. Increases above the recommended initial dose are recommended only after an appropriate clinical evaluation and should generally be made at intervals of at least 24 hours. If treatment with this medicine is discontinued, the dose should be reduced gradually and cautiously. 4) Acute treatment of depressive episodes associated with bipolar I disorder Start treatment with 5 mg of olanzapine once daily and increase to 10 mg once daily. Administer this medicine at bedtime and adjust the dose appropriately according to age and symptoms; do not exceed a daily dose of 20 mg. Food does not affect drug absorption, so this medicine may be taken with or without food. 2. Administration in special populations 1) Older adults Starting at a dose of 5 mg or less daily may be considered when sufficiently supported by clinical factors. 2) Patients with renal or hepatic impairment A low initial dose (5 mg) should be considered. In cases of moderate hepatic impairment (cirrhosis, Child-Pugh class A or B), the initial dose is 5 mg and should be increased cautiously. 3) Patients with multiple factors that delay the metabolism of this medicine (female sex, older age, and nonsmoking status) may also be started on a lower dose. 3. Precautions (for orally disintegrating tablets only) This medicine is fragile. Remove it from the outer package and open the blister by peeling off the metal foil on the back. Do not press the tablet through the metal foil when opening the blister. Immediately after opening the blister, remove the tablet with dry hands and place it directly in the mouth. The tablet disintegrates rapidly in saliva and may be swallowed with or without liquid.

This medication can cause a very serious side effect called Neuroleptic Malignant Syndrome, so if symptoms such as high fever, muscle stiffness, or changes in mental status appear, use should be stopped immediately and a healthcare professional should be consulted. This drug is not used for treating psychosis or behavioral disorders in patients with dementia, and caution should be exercised as there may be an increased risk of death and cerebrovascular problems in elderly dementia patients. Long-term use may lead to tardive dyskinesia, an involuntary movement disorder, and if symptoms occur, consideration should be given to reducing or discontinuing the dose. During the initial treatment period, it may take several weeks for effects to appear, so patient conditions should be closely monitored. Patients with diabetes or risk factors should regularly check blood sugar levels and pay attention to weight gain. Abruptly stopping the medication may result in symptoms such as sweating, insomnia, anxiety, and nausea, so it is recommended to taper off gradually. This drug may affect liver function, so patients with liver disease or elevated liver enzymes require regular liver function tests. Patients with cardiovascular diseases, elderly patients, or those at risk for hypotension should regularly check blood pressure and heart condition. Women who are pregnant or may become pregnant should consult a healthcare professional before administration as it may affect the fetus, and breastfeeding should be discontinued while taking this medication. This medication can cause drowsiness and dizziness, so caution is advised when driving or operating dangerous machinery. Additionally, this medication may interact with other drugs, so it is important to inform a healthcare professional or pharmacist of any other medications being taken. In case of overdose, there is no specific antidote, so immediate medical attention is required.

• High fever
• muscle rigidity
• changes in mental state
• irregular pulse
• changes in blood pressure
• tachycardia
• sweating
• cardiac arrhythmia
• increased creatine phosphokinase
• myoglobinuria

This medication should be stored in a tightly sealed container to prevent air and moisture from entering, ideally at room temperature between 15 to 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness and prevent degradation.

Appearance

White round film-coated tablets

Package unit

30 tablets (10 tablets/Alu-Alu X3)